Regenera to list in early June
Wednesday, 19 May, 2004
The CEO of Perth-based biotech Regenera, Tony Fitzgerald, said today that he expected the company’s offer to close next week, oversubscribed, ready for a June listing.
Regenra plans to raise AUD$8 million to develop its therapy for age related macular degeneration AMD – a condition in which damage to the retina causes visual impairment. The therapy involves injecting a steroid, triamciolone acetomide, into the back of the eye every six months.
“We have had a very good response in a difficult market,” said Fitzgerald. He said there had been significant Australian investment and that a number of international opthamologists were also supporting the company.
Fitzgerald plans to gain both TGA approval and an international licence for Regenera's product, possibly as a co-therapy with another AMD treatment.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
